Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

IL-8+ neutrophils drive inexorable inflammation in severe alcohol-associated hepatitis
Guan, Yukun , Peiffer, Brandon , Feng, Dechun , Parra, Maria A. , Wang, Yang , Fu, Yaojie , Shah, Vijay H. , Cameron, Andrew M. , Sun, Zhaoli , Peiffer, Brandon , Gao, Bin

Mayo Clinic

Journal of Clinical Investigation | March 19, 2024 | Volume: 134 | Issue: 9 | Pages: No page available

10.1172/jci178616 | PMID 38502218 Get It

Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐Enriched Rheumatoid Arthritis Patients
Fleischmann, Roy , Mysler, Eduardo , Greenwald, Maria , Ytterberg, Steven R. , Koch, Gary G., Bhatt, Deepak L. , Wang, Cunshan, Mikuls, Ted R. , Chen, All‐shine, Connell, Carol A., Woolcott, John , Menon, Sujatha, Chen, Yan , Lee, Kristen , Fleischmann, Roy , Mikuls, Ted R , Szekanecz, Zoltán , Bhatt, Deepak L , Charles‐Schoeman, Christina

Mayo Clinic

Arthritis & Rheumatology | March 14, 2024 | Volume: 76 | Issue: 8 | Pages: 1218-1229

10.1002/art.42846 | PMID 38481002 Get It

Objective The ORAL Surveillance trial found a dose‐dependent increase in venous thromboembolism (VTE) and pulmonary embolism (PE) events with tofacitinib versus tumor necrosis factor inhibitors (TNFi). We aimed to assess VTE incidence over time and explore risk factors of VTE, including disease activity, in ORAL Surveillance. Methods Patients with rheumatoid arthritis (RA) aged 50 years or older with at least one additional cardiovascular risk factor received tofacitinib 5 or 10 mg twice daily (BID) or TNFi. Post hoc, cumulative probabilities and incidence rates (patients with first events/100 patient‐years) by 6‐month intervals were estimated for adjudicated VTE, deep vein thrombosis, and PE. Cox regression models identified risk factors. Clinical Disease Activity Index leading up to the event was explored in patients with VTE. Results Cumulative probabilities for VTE and PE were higher with tofacitinib 10 mg BID, but not 5 mg BID, versus TNFi. Incidence rates were consistent across 6‐month intervals within treatments. Across treatments, risk factors for VTE included prior VTE, body mass index greater than or equal to 35 kg/m 2 , older age, and history of chronic lung disease. At the time of the event, most patients with VTE had active disease as defined by Clinical Disease Activity Index. Conclusion Incidences of VTE and PE were higher with tofacitinib (10 > 5 mg BID) versus TNFi and were generally consistent over time. Across treatments, VTE risk factors were aligned with previous studies in the general RA population. These data highlight the importance of assessing VTE risk factors, including age, body mass index, and VTE history, when considering initiation of tofacitinib or TNFi in patients with active RA.
Longitudinal Free‐Water Changes in Dementia with Lewy Bodies
Chiu, Shannon , Chen, Robin , Wang, Wei‐en , Armstrong, Melissa J. , Savica, Rodolfo , Fields, Julie A. , Graff‐Radford, Neill R., Ferman, Tanis J. , Kantarci, Kejal , Vaillancourt, David E. , Initiative, Alzheimer's Disease Neuroimaging, Chiu, Shannon Y , Savica, Rodolfo , Kantarci, Kejal , Ferman, Tanis J , Armstrong, Melissa J , Boeve, Bradley F. , Ramanan, Vijay K. , Graff‐Radford, Neill R. , Initiative, Alzheimer's Disease Neuroimaging

Mayo Clinic

Movement Disorders | March 13, 2024 | Volume: 39 | Issue: 5 | Pages: 836-846

10.1002/mds.29763 | PMID 38477399 Get It

AbstractBackgroundDiffusion‐weighted magnetic resonance imaging (dMRI) examines tissue microstructure integrity in vivo. Prior dementia with Lewy bodies (DLB) diffusion tensor imaging studies yielded mixed results.ObjectiveWe employed free‐water (FW) imaging to assess DLB progression and correlate with clinical decline in DLB.MethodsBaseline and follow‐up MRIs were obtained at 12 and/or 24 months for 27 individuals with DLB or mild cognitive impairment with Lewy bodies (MCI‐LB). FW was analyzed using the Mayo Clinic Adult Lifespan Template. Primary outcomes were FW differences between baseline and 12 or 24 months. To compare FW change longitudinally, we included 20 cognitively unimpaired individuals from the Alzheimer's Disease Neuroimaging Initiative.ResultsWe followed 23 participants to 12 months and 16 participants to 24 months. Both groups had worsening in Montreal Cognitive Assessment (MoCA) and Movement Disorder Society‐Unified Parkinson's Disease Rating Scale (MDS‐UPDRS) scores. We found significant FW increases at both time points compared to baseline in the insula, amygdala, posterior cingulum, parahippocampal, entorhinal, supramarginal, fusiform, retrosplenial, and Rolandic operculum regions. At 24 months, we found more widespread microstructural changes in regions implicated in visuospatial processing, motor, and cholinergic functions. Between‐group analyses (DLB vs. controls) confirmed significant FW changes over 24 months in most of these regions. FW changes were associated with longitudinal worsening of MDS‐UPDRS and MoCA scores.ConclusionsFW increased in gray and white matter regions in DLB, likely due to neurodegenerative pathology associated with disease progression. FW change was associated with clinical decline. The findings support dMRI as a promising tool to track disease progression in DLB. © 2024 International Parkinson and Movement Disorder Society.
Sustained Pericarditis Recurrence Risk Reduction With Long‐Term Rilonacept
Imazio, Massimo , Klein, Allan L. , Brucato, Antonio , Abbate, Antonio , Arad, Michael , Cremer, Paul , LeWinter, Martin M. , Lewis, Basil S. , Lin, David , Sutej, Paul, Wasserstrum, Yishay , Clair, JoAnn , Agarwal, Indra, Wang, Sheldon, Paolini, John F. , Investigators, for the RHAPSODY, Cremer, Paul C , LeWinter, Martin M , Lewis, Basil S , Luis, Sushil A , Wasserstrum, Yishay , Clair, JoAnn , Paolini, John F , Brucato, Antonio , Klein, Allan , Imazio, Massimo , Insalaco, Antonella , Luis, Sushil Allen , Nicholls, Stephen J. , Investigators, for the RHAPSODY

Mayo Clinic

Journal of the American Heart Association | March 12, 2024 | Volume: 13 | Issue: 6 | Pages: No page available

10.1161/jaha.123.032516 | PMID 38471825 Get It

Background Rilonacept, a once‐weekly interleukin‐1 alpha and beta cytokine trap, reduced pericarditis recurrence in the phase 3 study, RHAPSODY (Rilonacept Inhibition of Interleukin‐1 Alpha and Beta for Recurrent Pericarditis: A Pivotal Symptomatology and Outcomes Study). The RHAPSODY long‐term extension further explored recurrent pericarditis natural history and treatment duration decision‐making during 24 additional months of open‐label rilonacept treatment. Methods and Results Seventy‐four patients commenced the long‐term extension, with a median (maximum) total rilonacept duration of 22 (35) months. Individually, 18 months after the most proximal pericarditis recurrence, investigators decided to continue rilonacept on study, suspend rilonacept for off‐treatment observation (rescue allowed), or discontinue the study. The annualized incidence of pericarditis recurrence on rilonacept up to the 18‐month decision milestone was 0.04 events/patient‐year versus 4.4 events/patient‐year prestudy while on oral therapies. At the 18‐month decision milestone, 64% (33/52) continued rilonacept, 15% (8/52) suspended rilonacept for observation, and 21% (11/52) discontinued the study. Among the 33 patients (1/33; 3.0%) continuing rilonacept (median time to recurrence could not be estimated due to too few events), a single recurrence occurred 4 weeks after a treatment interruption. Among patients suspending rilonacept, 75% (6/8) experienced recurrence (median time to recurrence, 11.8 weeks [95% CI, 3.7 weeks to not estimable]). There was a 98% reduction in risk of pericarditis recurrence among patients continuing rilonacept treatment after the 18‐month decision milestone versus those suspending treatment for observation (hazard ratio, 0.02; P <0.0001). Conclusions In the RHAPSODY long‐term extension, continued rilonacept treatment resulted in continued response; treatment suspension at the 18‐month decision milestone was associated with pericarditis recurrence. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03737110.
NetActivity enhances transcriptional signals by combining gene expression into robust gene set activity scores through interpretable autoencoders
Ruiz-Arenas, Carlos , Marín-Goñi, Irene , Wang, Liewei , Ochoa, Idoia , Pérez‐Jurado, Luis A. , Hernáez, Mikel , Hernaez, Mikel , Marín-Goñi, Irene

Mayo Clinic

Nucleic Acids Research | March 12, 2024 | Volume: 52 | Issue: 9 | Pages: e44-e44

10.1093/nar/gkae197 | PMID 38597610 Get It

Abstract Grouping gene expression into gene set activity scores (GSAS) provides better biological insights than studying individual genes. However, existing gene set projection methods cannot return representative, robust, and interpretable GSAS. We developed NetActivity, a machine learning framework that generates GSAS based on a sparsely-connected autoencoder, where each neuron in the inner layer represents a gene set. We proposed a three-tier training that yielded representative, robust, and interpretable GSAS. NetActivity model was trained with 1518 GO biological processes terms and KEGG pathways and all GTEx samples. NetActivity generates GSAS robust to the initialization parameters and representative of the original transcriptome, and assigned higher importance to more biologically relevant genes. Moreover, NetActivity returns GSAS with a more consistent definition and higher interpretability than GSVA and hipathia, state-of-the-art gene set projection methods. Finally, NetActivity enables combining bulk RNA-seq and microarray datasets in a meta-analysis of prostate cancer progression, highlighting gene sets related to cell division, key for disease progression. When applied to metastatic prostate cancer, gene sets associated with cancer progression were also altered due to drug resistance, while a classical enrichment analysis identified gene sets irrelevant to the phenotype. NetActivity is publicly available in Bioconductor and GitHub.
A 3D dual‐echo spiral sequence for simultaneous dynamic susceptibility contrast and dynamic contrast‐enhanced MRI with single bolus injection
Li, Zhiqiang , Wang, Dinghui , Choudhary, Poonam, Ragunathan, Sudarshan , Karis, John P. , Pipe, James G. , Quarles, C. Chad , Stokes, Ashley M. , Ooi, Melvyn B. , Choudhary, Poonam

Mayo Clinic

Magnetic Resonance in Medicine | March 12, 2024 | Volume: 92 | Issue: 2 | Pages: 631-644

10.1002/mrm.30077 | PMID 38469930 Get It

AbstractPurposePerfusion MRI reveals important tumor physiological and pathophysiologic information, making it a critical component in managing brain tumor patients. This study aimed to develop a dual‐echo 3D spiral technique with a single‐bolus scheme to simultaneously acquire both dynamic susceptibility contrast (DSC) and dynamic contrast‐enhanced (DCE) data and overcome the limitations of current EPI‐based techniques.MethodsA 3D spiral‐based technique with dual‐echo acquisition was implemented and optimized on a 3T MRI scanner with a spiral staircase trajectory and through‐plane SENSE acceleration for improved speed and image quality, in‐plane variable‐density undersampling combined with a sliding‐window acquisition and reconstruction approach for increased speed, and an advanced iterative deblurring algorithm. Four volunteers were scanned and compared with the standard of care (SOC) single‐echo EPI and a dual‐echo EPI technique. Two patients were scanned with the spiral technique during a preload bolus and compared with the SOC single‐echo EPI collected during the second bolus injection.ResultsVolunteer data demonstrated that the spiral technique achieved high image quality, reduced geometric artifacts, and high temporal SNR compared with both single‐echo and dual‐echo EPI. Patient perfusion data showed that the spiral acquisition achieved accurate DSC quantification comparable to SOC single‐echo dual‐dose EPI, with the additional DCE information.ConclusionA 3D dual‐echo spiral technique was developed to simultaneously acquire both DSC and DCE data in a single‐bolus injection with reduced contrast use. Preliminary volunteer and patient data demonstrated increased temporal SNR, reduced geometric artifacts, and accurate perfusion quantification, suggesting a competitive alternative to SOC‐EPI techniques for brain perfusion MRI.
Albumin promoter-driven FlpO expression induces efficient genetic recombination in mouse liver
Zhu, Xiaohui, Yang, Yan , Feng, Dongfeng , Wang, Oliver , Chen, Jiaxiang , Wang, Jiale , Liu, Yang , Edenfield, Brandy , Haddock, Ashley , Bi, Yan , Ji, Baoan , Edenfield, Brandy H, Haddock, Ashley N, Bi, Yan , Ji, Baoan , Wang, Jiale , Zhu, Xiaohui, Wang, Oliver, Wang, Bin , Wang, Ying , Patel, Tushar

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | March 12, 2024 | Volume: 326 | Issue: 5 | Pages: G495-G503

10.1152/ajpgi.00263.2023 | PMID 38469630 Get It

A liver-specific Alb-FlpO mouse line was generated. By coupling it with other existing CreERT or Cre lines, the dual recombinase approach can enable sequential gene modifications within the same cell or across various cell types in an organism for liver research through temporal and spatial gene manipulations.
Defective transfer of parental histone decreases frequency of homologous recombination by increasing free histone pools in budding yeast
Karri, Srinivasu , Yang, Yi , Dickinson, Quinn , Jia, Jing , Huang, Yuxin , Wang, Zhiquan , Gan, Haiyun , Yu, Chuanhe , Yu, Chuanhe , Zhou, Jiaqi , Wang, Zhiquan

Mayo Clinic

Nucleic Acids Research | March 8, 2024 | Volume: 52 | Issue: 9 | Pages: 5138-5151

10.1093/nar/gkae205 | PMID 38554108 Get It

Abstract Recycling of parental histones is an important step in epigenetic inheritance. During DNA replication, DNA polymerase epsilon subunit DPB3/DPB4 and DNA replication helicase subunit MCM2 are involved in the transfer of parental histones to the leading and lagging strands, respectively. Single Dpb3 deletion (dpb3Δ) or Mcm2 mutation (mcm2-3A), which each disrupts one parental histone transfer pathway, leads to the other's predominance. However, the biological impact of the two histone transfer pathways on chromatin structure and DNA repair remains elusive. In this study, we used budding yeast Saccharomyces cerevisiae to determine the genetic and epigenetic outcomes from disruption of parental histone H3–H4 tetramer transfer. We found that a dpb3Δ mcm2-3A double mutant did not exhibit the asymmetric parental histone patterns caused by a single dpb3Δ or mcm2-3A mutation, suggesting that the processes by which parental histones are transferred to the leading and lagging strands are independent. Surprisingly, the frequency of homologous recombination was significantly lower in dpb3Δ, mcm2-3A and dpb3Δ mcm2-3A mutants, likely due to the elevated levels of free histones detected in the mutant cells. Together, these findings indicate that proper transfer of parental histones during DNA replication is essential for maintaining chromatin structure and that lower homologous recombination activity due to parental histone transfer defects is detrimental to cells.
Spontaneous Coronary Artery Dissection with Cardiogenic Shock in the United States
Krittanawong, Chayakrit , Patel, Neelkumar , Qadeer, Yusuf Kamran , Maitra, Neil Sagar , Sharma, Samin K. , Jneid, Hani , Bandyopadhyay, Dhrubajyoti , Wang, Zhen , Alam, Mahboob

Mayo Clinic

Reviews in Cardiovascular Medicine | March 8, 2024 | Volume: 25 | Issue: 3 | Pages: No page available

10.31083/j.rcm2503086 | PMID 39076947 Get It

Background: Spontaneous coronary artery dissection (SCAD) is defined as a non-traumatic separation of the epicardial coronary artery walls that creates a false lumen. SCAD poses a difficult challenge in management, as decisions regarding revascularization and medical management seem to be tailored to the individual patient. We evaluated and compared outcomes based on cardiogenic shock in patients with SCAD utilizing Nationwide Readmissions Database (NRD) between January 1, 2016, to December 30, 2020. Methods: We utilized the NRD 2016–2019 to carry out this study. We evaluated demographics (e.g., age, gender), conventional risk factors, comorbidities present on the index admission, and in-hospital outcomes using their specific ICD-10-CM codes. The primary outcomes were In-hospital mortality and 30-day readmission, and the secondary outcome was to compare the complications in SCAD patient with cardiogenic shock (CS) compared to those without CS. Results: We analyzed 2473 individuals with SCAD, 2199 of these individuals did not have cardiogenic shock whereas 274 of these individuals did have cardiogenic shock. When comparing SCAD with cardiogenic shock to SCAD without cardiogenic shock, there was a statistically significant increased odds ratio (OR) for death (propensity matched OR 24.93 (7.49–83.05), use of mechanical circulatory support (propensity matched OR 15.30 (6.87–34.04), ventricular tachycardia (propensity matched OR 4.45 (1.92–10.34), utilization of blood transfusions (propensity matched OR 3.82 (1.86–7.87), acute kidney injury (propensity matched OR 4.02 (1.45–11.13), need for mechanical ventilation (propensity matched OR 8.87 (3.53–22.31), and respiratory failure (propensity matched OR 4.95 (1.83–13.41)))))))). There was no statistically significant difference in 30-day readmission rates between the two groups. Conclusions: SCAD is a unique condition that can lead to many complications. In our analysis, we showed that SCAD associated with cardiogenic shock compared to SCAD not associated with cardiogenic shock results in greater odds of complications including death, use of mechanical circulatory support, need for blood transfusions, ventricular tachycardia, acute kidney injury, use of mechanical ventilation, and respiratory failure. SCAD with cardiogenic shock represents a significantly critical clinical scenario that requires a multi-disciplinary approach to prevent the many potential complications associated with this disease process.
UGT1A7 altered HER2-positive breast cancer response to trastuzumab by affecting epithelial-to-mesenchymal transition: A potential biomarker to identify patients resistant to trastuzumab treatment.
Yuan, Yuan , Wang, Cong , Bai, Chenguang , Zhang, Zhe , Zhou, Hao , Gao, Huanyao , Wang, Siwei

Mayo Clinic

No container title available | March 7, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3878357/v1 Get It

Abstract Background: HER2-positive (HER2+) breast cancer accounts for 20–30% of all breast cancers. Although trastuzumab has significantly improved the survival of patients with HER2+ breast cancer, more than 70% of patients develop drug resistance within one year of treatment. Understanding the molecular mechanisms of trastuzumab resistance and identifying biomarkers that predict early trastuzumab resistance would greatly benefit patients receiving trastuzumab therapy. Methods: Differential-gene-expression analysis of trastuzumab-sensitive and resistant HER2+ breast cancer cell lines from GSE15043 was performed to identify the biomarkers associated with trastuzumab resistance. Differential biomarker expression was confirmed in FFPE tissues collected from clinical HER2+ breast cancer tumor samples that were sensitive or resistant to trastuzumab treatment. The function of the biomarkers associated with trastuzumab resistance was studied using western blotting, immunofluorescence, electron microscopy, and siRNA knockdown and overexpression to elucidate the role and mechanisms of the biomarker in affecting the trastuzumab response. Results: UGT1A7, a member of the uronic acid transferase family, was associated with trastuzumab resistance. UGT1A7 expression was downregulated in trastuzumab-resistant tumor tissues and in a cell line that developed trastuzumab resistance (BT474TR). Overexpressing UGT1A7 in BT474TR restored their sensitivity to trastuzumab treatment, whereas downregulating UGT1A7 expression in parental cells led to trastuzumab resistance. Importantly, UGT1A7 localized to the endoplasmic reticulum and altered stress responses. Furthermore, downregulating UGT1A7 expression promoted epithelial-to-mesenchymal transition (EMT) by affecting TWIST, SNAIL, and GRP78 expression and the AMP-activated protein kinase signaling pathway, thus contributing to trastuzumab resistance. Conclusions: This study demonstrated the important role and novel mechanisms of UGT1A7 in tumor responses to trastuzumab. Low UGT1A7 expression plays an important role in EMT and contributes to trastuzumab resistance. UGT1A7 has the potential to be developed as a biomarker for identifying patients who are resistant to trastuzumab treatment.